{"schema_version":"1.0","type":"article","title":"Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot","url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.md","lang":"en","date":"2026-07-07","publish_at":"2026-07-07T08:49:37+08:00","updated_at":"2026-07-07","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","ADC","PD-1/VEGF","bispecific antibody","oncology","BD licensing","clinical data","drug development","biotech valuation","Big Pharma"],"summary":"After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone.","key_points":[],"facts":[],"sections":["01｜Sigvotatug Vedotin's Setback Is Not Just One Failed Trial","02｜The Seagen Deal Was Pfizer's Make-Up Exam After Missing the PD-1 Golden Decade","03｜As Single-Agent ADCs Get Harder, Combinations Become the Next Battlefield","04｜Why PD-1/VEGF? Because It Tries to Touch Both Immunity and Angiogenesis","05｜ClinicalTrials.gov Shows Pfizer Is Already Spreading PF-08634404 Broadly","06｜What Pfizer May Really Want to Replicate Is the PADCEV + Keytruda Logic","07｜How Taiwan Investors Should Read It: Do Not Stop at \"ADC Concept Stock\"","08｜The Real Risk: Bispecifics Are Not Magic, and ADCs Are Not Untouchable","Conclusion｜Pfizer Is Not Only Betting on ADCs. It Is Rebuilding an Oncology Backbone."],"references":[{"title":"Pfizer, [Pfizer Completes Acquisition of Seagen](), December 14, 2023.","source":"","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen"},{"title":"Pfizer, [Pfizer Completes Licensing Agreement with 3SBio](), July 24, 2025.","source":"","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio"},{"title":"ClinicalTrials.gov, [NCT06012435: SGN-B6A versus docetaxel in previously treated NSCLC]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06012435"},{"title":"ClinicalTrials.gov, [NCT06758401: sigvotatug vedotin plus pembrolizumab in PD-L1 high NSCLC]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06758401"},{"title":"ClinicalTrials.gov, [NCT07227298: PF-08634404 combination study in advanced cancers]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07227298"},{"title":"ClinicalTrials.gov, [NCT07222566: PF-08634404 plus chemotherapy in NSCLC]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07222566"},{"title":"ClinicalTrials.gov, [NCT07226999: PF-08634404 in extensive-stage small cell lung cancer]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07226999"},{"title":"ClinicalTrials.gov, [NCT07421700: PF-08634404 plus enfortumab vedotin in urothelial cancer]().","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07421700"},{"title":"Disclaimer: This article is for industry research and market observation only. It does not constitute investment advice, trading advice, medical advice, fundraising advice, or a recommendation on any individual security. Biotech and pharmaceutical investing involves clinical, regulatory, licensing, commercialization, currency, and capital-market risks. Readers should make independent judgments and bear their own risk.","source":"","date":"","url":""}],"images":[{"alt":"Pfizer oncology reset","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-01.png"},{"alt":"Why PD-1/VEGF matters","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-02.png"},{"alt":"Combination engine","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-03.png"},{"alt":"Taiwan investor lens","url":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-07）。Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot。https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}